There are strategies for screening and prevention of cervical cancer

Abstract

The epidemiological situation of cervical cancer is assessed as unsatisfactory in Russia. The morbidity rate is one of the highest in Europe, and morbidity and mortality rates continue to increase. There were 12,201 new cases of cervical malignant lesions, 6,322 women in our country died from this disease, and the mortality rate was 9.6 per 100,000 women in 2021. At the same time, cervical cancer is one of the few nosological forms of malignant neoplasms that can currently be prevented through vaccination. The disease is suitable for population screening for secondary prevention. Large-scale vaccination against human papillomavirus and properly organized population screening have reduced the mortality rate from cervical cancer to 2 cases per 100 thousand women in 2020 in Australia. If the country continues to stay the course, by 2034 the number of fatalities will be less than 1 in 100,000 per year. The article provides an analysis of current approaches to screening and prevention of cervical cancer worldwide to determine a more effective strategy. We anticipate that the collaborative actions of a health care organization, motivated health care providers, and women interested in their health will lead to a positive trend in cervical cancer prevention in our state.

Keywords

сervical cancer / cervical dysplasia / cervical screening / HPV / HPV vaccination / human papillomavirus / screening

References

[1] Zaridze DG, Maksimovich DM, Stilidi IS. Cervical cancer and other HPV associated tumors in Russia. Voprosy onkologii. 2020;66(4):325–335. (In Russ.) EDN: BLQLHH doi: 10.37469/0507-3758-2020-66-4-325-335

[2] Заридзе Д.Г., Максимович Д.М., Стилиди И.С. Рак шейки матки и другие ВПЧ ассоциированные опухоли в России // Вопросы онкологии. 2020. Т. 66, № 4. С. 325–335. EDN: BLQLHH doi: 10.37469/0507-3758-2020-66-4-325-335

[3] Maksutova DZh, Gappar G, Zaydin G, et al. Organization and system of screening measures for cervical cancer (literature review). Medicus. 2021;3(39):15–24. (In Russ.) EDN: JWAPCP

[4] Максутова Д.Ж., Гаппар Г., Зайдин Г., и др. Организация и система скрининговых мероприятий рака шейки матки (обзор литературы) // Medicus. 2021. Т. 3, № 39. С. 15–24. EDN: JWAPCP

[5] Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169–182. doi: 10.1016/S0140-6736(18)32470-X

[6] Cohen P.A., Jhingran A., Oaknin A., Denny L. Cervical cancer // Lancet. 2019. Vol. 393, N. 10167. P. 169–182. doi: 10.1016/S0140-6736(18)32470-X

[7] Antonishyn NA. The utility of PV typing and relative quantification of PV-16 transcripts for monitoring PV vaccine efficacy and improving colposcopy triage of women with abnormal cervical cytology [dissertation]. Regina, Saskatchewan: University of Regina; 2007.

[8] Antonishyn N.A. The utility of PV typing and relative quantification of PV-16 transcripts for monitoring PV vaccine efficacy and improving colposcopy triage of women with abnormal cervical cytology [dissertation]. Regina, Saskatchewan: University of Regina, 2007.

[9] Aristova AS, Gulyaeva IL. Modern conception of etiology, pathogenesis, main directions of diagnosis, treatment and prevention of cervical canser. European Journal of natural history. 2021;2:52–57. (In Russ.)

[10] Аристова А.С., Гуляева И.Л. Современные представления об этиологии, патогенезе, основных направлениях диагностики, лечения и профилактики рака шейки матки // European Journal of natural history. 2021. Т. 2. С. 52–57.

[11] Jalil AT, Karevskiy AE. Role of HPV 16 genotype in pathology of Cervical Cancer. Journal of the Grodno State Medical University. 2022;20(2):137–143. doi: 10.25298/2221-8785-2022-20-2-137-143

[12] Jalil A.T., Karevskiy A.E. Role of HPV 16 genotype in pathology of Cervical Cancer // Journal of the Grodno State Medical University. 2022. Vol. 20, N. 2. P. 137–143. doi: 10.25298/2221-8785-2022-20-2-137-143

[13] Wang SS, Zuna RE, Wentzensen N, et al. HPV cofactors by disease progression and HPV types in the Study to Understand Cervical Cancer Early Endpoints and Determinants. Cancer Epidemiol Biomarkers Prev. 2009;18(1):113–120. doi: 10.1158/1055-9965.EPI-08-0591

[14] Wang S.S., Zuna R.E., Wentzensen N., et al. HPV cofactors by disease progression and HPV types in the Study to Understand Cervical Cancer Early Endpoints and Determinants // Cancer Epidemiol Biomarkers Prev. 2009. Vol. 18, N. 1. P. 113–120. doi: 10.1158/1055-9965.EPI-08-0591

[15] Castellsagué X, Muñoz N. Chapter 3: Cofactors in HPV Carcinogenesis — Role of Parity, Oral Contraceptives and Tobacco Smoking. JNCI Monographs. 2003;(31):20–28. doi: 10.1093/oxfordjournals. jncimonographs.a003477

[16] Castellsagué X., Muñoz N. Chapter 3: Cofactors in HPV Carcinogenesis — Role of Parity, Oral Contraceptives and Tobacco Smoking // JNCI Monographs. 2003. N. 31. P. 20–28. doi: 10.1093/oxfordjournals. jncimonographs.a003477

[17] Brusselaers N, Shrestha S. van de Wijgert J, Verstraelen H. Vaginal dysbiosis and the risk of HPV and cervical cancer: systematic review and meta-analysis. Am J Obstet. Gynecol. 2019;221(1):9–18. doi: 10/1016/j.ajog.2018.12.011

[18] Brusselaers N., Shrestha S., van de Wijgert J., Verstraelen H. Vaginal dysbiosis and the risk of HPV and cervical cancer: systematic review and meta-analysis // Am. J. Obstet. Gynecol. 2019. Vol. 221, N. 1. P. 9–18. doi: 10/1016/j.ajog.2018.12.011

[19] Aliyeva MT, Shmidt AA, Ivanova LV, Khachaturova NV. Peculiarities of incidence, diagnostics and therapy of human papilloma virus among female soldiers, military students of higher military educational institutions of the Ministry of defence of the Russian Federation. Bulletin of the Russian Military Medical Academy. 2013;44(4):151–154. (In Russ.) EDN: RPTIPF

[20] Алиева М.Т., Шмидт А.А., Иванова Л.В., Хачатурова Н.В. Особенности заболеваемости, диагностики и терапии вируса папилломы человека среди военнослужащих женщин-курсантов высших военных учебных заведений МО РФ // Вестник Российской военно-медицинской академии. 2013. Т. 44, № 4. С. 151–154. EDN: RPTIPF

[21] Leshcheva MYu, Astapenko EF, Gabbasova NV. Topical aspects of etiology and prevention of cervical cancer. Tumors of female reproductive system 2022;18(1):97–102. (In Russ.) EDN: VNXKHD doi: 10.17650/1994-4098-2022-18-1-97-102

[22] Лещева М.Ю., Астапенко Е.Ф., Габбасова Н.В. Актуальные аспекты этиологии и профилактики рака шейки матки // Опухоли женской репродуктивной системы. 2022. Т. 18, № 1. С. 99–102. EDN: VNXKHD doi: 10.17650/1994-4098-2022-18-1-97-102

[23] Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019;4(1):19–27. doi: 10.1016/S2468-2667(18)30183-X

[24] Hall M.T., Simms K.T., Lew J.B., et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study // Lancet Public Health. 2019. Vol. 4. N. 1. P. 19–27. doi: 10.1016/S2468-2667(18)30183-X

[25] Kjaer SK, Nygard M, Dillner J, et al. 12-year follow-up on the long-term effectiveness of the quadrivalent Human Papillomavirus Vaccine in 4 Nordic countries. Clin Infect Dis. 2018;66(3):339–345. doi: 10/1093/cid/cix797

[26] Kjaer S.K., Nygard M., Dillner J., et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent Human Papillomavirus Vaccine in 4 Nordic countries // Clin. Infect. Dis. 2018. Vol. 66, N. 3. P. 339–345. doi: 10/1093/cid/cix797

[27] Falcaro M, Castañon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084–2092. doi: 10.1016/S0140-6736(21)02178-4

[28] Falcaro M., Castañon A., Ndlela B., et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study // Lancet. 2021. Vol. 398, N. 10316. P. 2084–2092. doi: 10.1016/S0140-6736(21)02178-4

[29] Minkina GN. Achievements and prospects of vaccination against human papillomavirus and associated diseases. Epidemiology and Vaccination. 2020;19(2):110–118. (In Russ.) doi: 10.31631/2073-3046-2020-19-2-110-118

[30] Минкина Г.Н. Достижения и перспективы вакцинопрофилактики папилломовирусной инфекции и ассоциированных заболеваний // Эпидемиология и вакцинопрофилактика. 2020. Т. 19, № 2. С. 110–118. doi: 10.31631/2073-3046-2020-19-2-110-118

[31] Shmidt AA, Alieva MT, Ivanova LV, Molchanov OV. The role of the vaccine prophylaxis of cervical cancer among female military personnel. Military Medical Journal. 2015;336(6):30–33. (In Russ.) EDN: WELGKL doi: 10.17816/RMMJ73901

[32] Шмидт А.А., Алиева М.Т., Иванова Л.В., Молчанов О.В. Роль вакцинопрофилактики рака шейки матки у женщин-военнослужащих // Военно-медицинский журнал. 2015. Т. 336, № 6. С. 30–33. EDN: WELGKL doi: 10.17816/RMMJ73901

[33] Prilepskaya VN, Apolikhina IA, Nazarova NM, Malyshkina DA. Cervical cancer screening. Obstetrics and Gynecology. 2020;(S9):4–6. (In Russ.) EDN: PDBMLN

[34] Прилепская В.Н., Аполихина И.А., Назарова Н.М., Малышкина Д.А. Скрининг рака шейки матки // Акушерство и гинекология. 2020. S9. С. 4–6. EDN: PDBMLN

[35] Rodriguez AM, Zeybek B, Vaughn M, et al. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study. Cancer. 2020;126(8):1656–1667. doi: 10.1002/cncr.32700

[36] Rodriguez A.M., Zeybek B., Vaughn M., et al. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study // Cancer. 2020. Vol. 126, N. 8. P. 1656–1667. doi: 10.1002/cncr.32700

[37] Brotherton JM, Budd A, Rompotis C, et al. Is one dose of human papillomavirus vaccine as effective as three? A national cohort analysis. Papillomavirus Res. 2019;8:100177. doi: 0.1016/j.pvr.2019. 100177

[38] Brotherton J.M., Budd A., Rompotis C., et al. Is one dose of human papillomavirus vaccine as effective as three? A national cohort analysis // Papillomavirus Res. 2019. Vol. 8. Art. 100177. doi: 0.1016/j.pvr.2019. 100177

[39] Brotherton JML, Sundström K. More evidence suggesting that 1-dose human papillomavirus vaccination may be effective. Cancer. 2020;126(8):1602–1604. doi: 10.1002/cncr.32696

[40] Brotherton J.M.L., Sundström K. More evidence suggesting that 1-dose human papillomavirus vaccination may be effective // Cancer. 2020. Vol. 126, N. 8. P. 1602–1604. doi: 10.1002/cncr.32696

[41] Elgina SI, Zolotorevskaya OS, Zakharov IS et al. Cytological screening for cervical cancer diagnosing. Mother and Baby in Kuzbass. 2019;(3(78)):37–40. (In Russ.)

[42] Елгина С.И., Золоторевская О.С., Захаров И.С., и др. Цитологический скрининг в диагностике рака шейки матки // Мать и дитя в Кузбассе. 2019. № 3 (78). С. 37–40.

[43] Volchenko NN, Sushinskaya TV, Borisova OV, et al. Comparative analysis of conventional and liquid-based cytological methods for cervical smears. Research’n Practical Medicine Journal. 2019;6(1):83–90. (In Russ.) EDN: RDKENA doi: 10.17709/2409-2231-2019-6-1-8

[44] Волченко Н.Н., Сушинская Т.В., Борисова О.В., и др. Сравнительный анализ традиционной и жидкостной цитологии мазков из шейки матки // Исследования и практика в медицине. 2019. Т. 6, № 1. С. 83–90. EDN: RDKENA doi: 10.17709/2409-2231-2019-6-1-8

[45] Zhurman VN, Maslennikova TYu, Eliseeva EV, Matyushkina LS. Effectiveness of liquid-based cytology as cervical cancer screening. Ulyanovsk Medico-Biological Journal. 2022;(4):6–18. (In Russ.) EDN: DICLZV doi: 10.34014/2227-1848-2022-4-6-18

[46] Журман В.Н., Масленникова Т.Ю., Елисеева Е.В., Матюшкина Л.С. Эффективность жидкостной цитологии как скрининга рака шейки матки // Ульяновский медико-биологический журнал. 2022. № 4. С. 6–18. EDN: DICLZV doi: 10.34014/2227-1848-2022-4-6-18

[47] Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321–346. doi: 103322/caac.21628

[48] Fontham E.T.H., Wolf A.M.D., Church T.R., et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society // CA Cancer J. Clin. 2020. Vol. 70, N. 5. P. 321–346. doi: 103322/caac.21628

[49] US Preventive Services Task Force; Curry SJ, Krist AH, Owens DK, et al. Screening for cervical cancer. US Preventive Services Task Force recommendation statement. JAMA. 2018;320(7):674–686. doi: 10.1001/jama.2018.10897

[50] US Preventive Services Task Force; Curry S.J., Krist A.H., Owens D.K., et al. Screening for cervical cancer. US Preventive Services Task Force recommendation statement // JAMA. 2018. Vol. 320, N. 7. P. 674–686. doi: 10.1001/jama.2018.10897

RIGHTS & PERMISSIONS

Eco-Vector